Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint
Executive Summary
New claim for platinum-resistant recurrent disease based on a median 3.4-month improvement in progression-free survival – with favorable trends in overall survival, overall response rate and duration of response – confirms agency’s willingness to entertain a progression endpoint in this tumor type.
You may also be interested in...
FDA Finally Approves Avastin In First-Line Ovarian Cancer
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands
The latest drug development news and highlights from our FDA Performance Tracker.
AstraZeneca’s Olaparib Clears FDA For Later Therapy Line In Ovarian Cancer
AstraZeneca’s Lynparza was rejected as a maintenance therapy after second-line treatment by an FDA advisory committee, but landed accelerated approval for heavily pretreated relapsed patients, based on data not considered in the initial advisory committee review.